Background: Adding the m-opioid receptor agonist remifentanil to agents used to induce general anaesthesia in elec-
Electroconvulsive therapy (ECT) is an effective treatment option for severe and treatment-resistant depression. 1 The mechanism of action of ECT is still not completely understood, but it is dependent on the seizure activity and termination. 2, 3 Several ictal electroencephalographic (EEG) characteristics have been proposed as markers of therapeutic efficacy. 4 ECT is performed under general anaesthesia to avoid the patient being conscious when the electrical stimulus is applied and to allow for the administration of a neuromuscular blocking agent, thus preventing the experience of being awake and paralysed. The available anaesthetic agents all have different advantages and disadvantages, 5 and the ideal anaesthetic agent for ECT is still debated. 6 The most commonly used anaesthesia induction agents in ECT are propofol and the barbiturates, thiopental and methohexital. Both propofol and barbiturates partially antagonise the induced seizure via a potent anticonvulsant effect. 5 To lessen this unwanted effect, the use of the short-acting m-opioid receptor agonist, remifentanildwhich does not increase the seizure thresholddin addition to an induction agent has been suggested. 7 Adding remifentanil reduces the required dose of anaesthesia induction agents, and thus, also some of their unfavourable effects on seizure threshold and parameters of seizure adequacy. 8 Several studies have evaluated the effect of adjunctive remifentanil on seizure parameters. 8e20 Although seizure duration is regarded as a poor predictor of the therapeutic response, and other electrophysiological seizure parameters have been proposed as measures for seizure adequacy, 3, 4 numerous studies have used seizure duration as the primary outcome. These studies have demonstrated that adjunctive remifentanil and a lower dose of the induction agent are associated with longer seizure duration.
8e13,18e20
Porter and colleagues 8 also found the post-ictal suppression index to be higher when adding remifentanil to propofol, and Dinwiddie and colleagues 13 similarly reported a greater degree of sustained inter-hemispheric EEG coherence. However, none of these studies assessed long-term clinical outcomes in terms of the anti-depressive efficacydany long-term clinical benefits of the routine use of remifentanil have therefore never been established. Data on response and remission rates after ECT, and tolerability, are still missing. Thus, the aim of the present retrospective register-based cohort study was to determine whether the use of routine adjunction of remifentanil was associated with favourable long-term treatment effects in terms of response and remission rates, speeds of response and remission, and side-effects.
Methods
The data in the current study came from a qualityimprovement project examining if the ECT units at Stavanger University Hospital and Bergen University Hospital were providing treatments of the same quality. All Norwegian acute psychiatric services are public, catchment area based and available to everyone. Both study hospitals provide specialised psychiatric healthcare and serve as local hospitals for all patients in their respective catchment areas. The populations in the catchment areas are demographically similar and the criteria for providing ECT treatment are the same in the two hospitals, as are the exclusion criteria. Thus, there should not be any significant differences between the two populations assessed in the study. Both units report to the Regional Register for Neurostimulation Treatment in Western Norway, 21 and they participated in the Norwegian RCT of ECT in bipolar disorder, in which all participating centres performed ECT according to standardised procedures as described in the study protocol. 22 However, one main difference remained between the two centres: remifentanil was routinely added to the induction anaesthetic agent in Stavanger, but not in Bergen. The present longitudinal register-based study of the two ECT units included all patients who had provided written consent to the register for the use of their data.
Ethics
The research protocol was submitted for consideration to the Regional Ethical Committee, and deemed exempt from review as it was classified as quality improvement (2016/973). This quality-improvement project was approved by the Data Protection Official for Research (approval no. 2016/4978). All patients provided written consent for the use of their data in the Regional Register for Neurostimulation Treatment in Western Norway, which was approved by the Norwegian Data Protection Authority (approval no. 2012/5490).
Electroconvulsive therapy
ECT was administered with the Thymatron System IV (Somatics, Lake Bluff, IL, USA). The preference was for the shortacting anaesthetic, thiopental, to be used at the minimum dose required to obtain anaesthesia. Another induction agent (propofol or etomidate) could be used if indicated. When the patient reached unconsciousness, succinylcholine at a dose of 0.5e1.0 mg kg À1 was administered as a neuromuscular blocking agent. All patients were hyper-oxygenated before applying electric stimulation. The stimulus was typically provided 60e90 s after administering succinylcholine.
At Stavanger University Hospital (Rþ), remifentanil (1 mg kg
À1
) was administered routinely in all patients just before the induction agent, whereas remifentanil was not used at Bergen University Hospital (Re); this difference is attributable to one of the aforementioned studies performed at Stavanger University Hospital. 10 That was a prospective, randomised, double-blind crossover trial that assessed seizure duration, haemodynamic response, and recovery time, and demonstrated that the seizure duration was significantly longer (39% increase) when adding remifentanil 1 mg kg À1 and concomitantly reducing the dose of barbiturate anaesthesia. Based on that study, remifentanil has been used routinely as an adjunct in ECT anaesthesia procedures performed at Stavanger University Hospital.
Editor's key points
Electroconvulsive therapy under brief general anaesthesia is an effective treatment for severe depression. An opioid is commonly co-administered to reduce the hypnotic dose requirement, as hypnotic agents generally have anti-convulsant effects. In this retrospective study, the authors studied remifentanil co-administration with thiopentone. Adjunctive remifentanil did not produce better longerterm outcomes and was associated with more shortterm adverse effects.
The preference was for the stimulus to be applied via right unilateral (RUL) electrode placement and with a pulse width of 0.5 ms. Bilateral electrode placement or an ultra-brief pulse width (0.25 ms) could be used if indicated. The initial stimulus energy was determined by an age-based method. 23 If a sufficient seizuredas determined by the clinicians based on seizure duration, d waves, and clinical effectdwas not obtained in one session, the stimulus parameters were adjusted in the next session. During the ECT courses, the patients remained under the care of their own treating psychiatrist, whilst deciding on concomitant psychopharmacological and somatic medications and the number of treatments. ECT was usually terminated when the patient achieved remission, experienced intolerable side-effects, or no further improvement was expected.
Patients
From June 2013 to October 2016, 227 patients received a total of 304 ECT courses, whilst 172 patients (76%) consented to their data being added to the register (234 ECT courses). Forty-five of the 172 patients received repeated treatment courses during the registration period (62 courses). Out of these 172 patients, 166 received treatment for a major depressive episode (uni-or bipolar depression) as the main diagnosis providing the indication for ECT. The six patients with primary diagnoses other than major depression were excluded from the analyses. In this study, we only used data from the first registered treatment courses for each patient [n Rþ ¼47 (541 sessions) and n Re ¼119 (1166 sessions)].
Assessments
Symptom intensity was assessed within 1 week before the start of treatment, weekly during treatment (to a maximum of 8 data points), and at 1e3 days after the final treatment session by the treating clinicians (psychiatrists, psychologists, and psychiatric nurses) using the Montgomery and Å sberg Depression Rating Scale (MADRS), 24 the Mini-Mental State Examination, 25 and the Clinical Global Impression (CGI) scale. 26 Response was defined as a reduction of at least 50% in the baseline MADRS score, whilst remission was defined as a MADRS score of 12 or less. The times to response and remission were defined as the number of days between the start of treatment and the first time reaching a MADRS score of equal to or lower than half of the baseline MADRS score and a MADRS score of 12 or less, respectively.
Further, each patient was assessed before each treatment by an ECT nurse for side-effects after the previous treatment (muscle aches, nausea, dizziness, headache, and subjective cognitive complaints). The answers provided by the patients were recorded on a Likert scale from 1 to 7, where 1 is 'not at all' and 7 is 'extremely'. The patients were categorised as 'experienced a side-effect' if their mean Likert scale across all treatments was !2.
Recording of treatment parameters
The anaesthetic drugs and the delivered charge were registered for each ECT session.
Statistical analysis
The characteristics of the patients at the two treatment units were compared using t-tests for normally distributed continuous variables, ManneWhitney U-tests for nonnormally distributed continuous variables, and c 2 tests for categorical variables. The percentages of patients achieving response or remission and experiencing side-effects were compared using c 2 tests.
A Cox proportional hazards model was used to determine whether Rþ and Re patients differed in the time to response and remission, adjusting for age and sex, and considering baseline MADRS score and thiopental dose as potential confounders. The best model fit was determined by a combination of a likelihood ratio test and checking whether the estimate of remifentanil groups changed substantially by the removal of non-significant effects. Further, as the exact moment for remission and response was unknown, the data were considered arbitrarily interval censored, and another set of analyses had the Cox model configured accordingly.
All time-to-event analyses were performed in R version 3.4.1 using the survival package, 27, 28 and the icenReg package for interval-censored models. 29 Time-to-event figures were created in R with the package ggplot2. 30 Other statistical tests were performed using the Statistical Package for the Social Sciences (version 23.0; SPSS, Chicago, IL, USA). The cut-off for statistical significance was set to a¼0.05 for all tests.
Results

Baseline patient and clinical characteristics
None of the baseline patient or clinical characteristics differed significantly between the remifentanil-treated patients (Rþ) and patients not treated with remifentanil (Re), as listed in Table 1 .
Treatment variables
The mean dosage of thiopental was significantly lower in Rþ patients, whereas there were no inter-group differences in the number of treatments, the dose of succinylcholine, or the delivered ECT charge (Table 2) . Treatments were usually given with RUL electrode placement, except in three Re patients, who received treatment with bilateral electrode placement (comprising a total of 28 stimulations). Most of the patients received a stimulus with an impulse width of 0.5 ms, with none of the Rþ patients and 21 (17.6%) of the Re patients receiving ECT with a 0.25 ms impulse width.
Symptom severity before and after treatment
The patients in both groups showed similar symptom severity and global cognitive functioning before ECT (Fig. 1) . Re patients scored higher on the MADRS, but not on the CGI. The symptom scores decreased from pre-to post-treatment in both treatment groups (analyses not shown), as presented in Fig. 1 . MADRS scores were available for 149 of the 166 patients before and after treatment. Most of the patients in both treatment groups responded to treatment (n Rþ ¼31 and n Re ¼85), with no significant inter-group difference (75.6% vs 75.9% responders in the Rþ and Re groups, respectively). Remission occurred during treatment in 63.4% and 64.6% of those in the Rþ and Re groups, respectively (non-significant). Patients achieving remission (n Rþ ¼26 and n Re ¼73) received significantly more treatments if they were treated with remifentanil compared with receiving no remifentanil treatment (mean of 10.8 vs 8.5 treatments; P¼0.026).
Time to response and remission
Cox regression and survival analyses with sex, age, and baseline MADRS as potential confounders revealed a longer time to response for Rþ patients [hazard ratio (HR)¼0.49; confidence interval (CI): 0.3e0.8; P¼0.004; Fig. 2A ), but no differences in the time to remission (HR¼0.68; CI: 0.4e1.2; P¼0.156; Fig. 2B ), as presented in Table 3A , whereas the results from the interval-censored Cox model showed a longer time to response for Rþ patients (HR¼0.59; CI: 0.4e0.8; P¼0.001) and a longer time to remission (HR¼0.72; CI: 0.5e1.0; P¼0.024); Table 3B .
Side-effects
A higher proportion of the Rþ patients reported side-effects of nausea, dizziness, and headache, whilst there were no differences between Rþ and Re patients in the incidence of muscle aches and subjective cognitive complaints (Table 4) .
Discussion
This is the first analysis of data on the long-term clinical efficacy of ECT with or without the addition of the short-acting opioid, remifentanil, to barbiturate anaesthesia. Overall, there was a substantial improvement in depressive The primary aim of this study was to determine whether the routine use of remifentanil as an adjunct to ECT anaesthesia is beneficial for patients in terms of improving the treatment efficacy or tolerability. Remifentanil would be advantageous as an adjunct to induction agents if at least one of the following could be demonstrated: a higher proportion of patients responding or remitting, fewer treatments, more rapid response or remission, and a reduction of side-effects. None of these criteria were met in the current study, and there were even contrary results regarding the rapidity of response and the tolerability. The patients treated with remifentanil exhibited a longer time to response and remission, and experienced more frequent side-effects of nausea, dizziness, and headache.
The observations made by Bortolotti 31 support our finding of a longer time to response and remission when using remifentanil. His analysis of data from a quality register (involving 109 ECT courses: 77 without and 32 with remifentanil and reduced-dose thiopental) revealed that the ECT course was longer with remifentanil than when remifentanil was not administered in patients younger than 65 yr. The longer time to response in the remifentanil-treated patients might be surprising, given the expectations of more favourable EEG seizure parameters 8, 13 that should translate into better clinical outcomes. There are several possible explanations for this observation: (i) More severely ill patients are expected to respond more rapidly. 32 The Re patients presented more severe pretreatment symptoms (i.e. higher MADRS scores), which might explain the tendency for less treatment sessions being necessary for response. We attempted to account for this potential source of error by adjusting for baseline MADRS score in the models, and found that it indeed had an effect in time to response, but only partly explains the shorter time to response (and not to remission). (ii) Remifentanil was administered to reduce the dose of thiopental. As intended, the mean dose of thiopental was significantly lower in Rþ patients, but the difference between Rþ and Re patients was numerically small (about 10%) compared with the reductions of about 33% in the doses of induction agents applied in other remifentanil studies. 9, 10 Thiopental was considered a potential confounder in the Cox models, but showed a non-significant effect in all potential model combinations (data not shown). Nevertheless, it is not known whether a further reduction in thiopental dose would have changed the model outcome. (iii) Based on the results of a study by Sullivan and colleagues, 33 it has been speculated that remifentanil can inhibit the induction of anticonvulsant processes that are critical to the efficacy of ECT. 34 However, this was only one of several possible interpretations of the study results, and no subsequent studies have confirmed the validity of this assumption. This notion should thus be interpreted with caution, also as a possible explanation for the results obtained in the current study. The use of remifentanil in general anaesthesia is associated with nausea. 35 In line with this, the remifentanil-treated patients more frequently reported nausea after each treatment session, along with headache and dizziness. Although the discomfort was only of mild-to-moderate intensity and transient, this could reduce the acceptance of the treatment. This study has the strength of including a relatively large sample, but there are also several limitations that should be considered. One obvious limitation is the retrospective design and the comparison between two different study centres, rather than comparing between the use and non-use of remifentanil. However, the data in the current study were collected at two university hospitals that had previously participated in a multicentre study involving uniform treatment procedures. Moreover, there has been an extensive collaboration between the clinicians at the two treatment units regarding the treatment protocol, internal revision of treatment quality, the quality register, and a previous RCT on ECT in bipolar disorder. We would, therefore, argue that the differences in treatment routines between the hospitals are likely to merely be in the use of remifentanil, and hence, that the treatment was administered in fairly similar ways, although there might have been differences in the timing of the ECT procedure. The interval between the administration of the induction agent and the electric stimulus influences the seizure quality. 36 This interval might differ between patients, although a stopwatch was used in Bergen (Re) and a wall clock with a second hand was used in Stavanger (Rþ) to ensure that the electric stimulus was given 60e90 s after the administration of the neuromuscular blocking agent. Applying the electric stimulus too soon after administering the induction agentdwhen the blood and brain concentrations of the induction agent are at their highestdcould result in seizures of inferior quality. 36 Thus, the use of different timing procedures might have influenced the concentration of the induction agent, and thus, the seizure quality.
As the study did not have a randomised design, it is not possible to draw definitive conclusions about causality, and thus, the clinical relevance of the current findings. In addition, as the data were collected in a clinical setting, no inter-rater reliability training was provided for the MADRS scores or the assessments of side-effects.
Another shortcoming of the current study is the lack of control for the use of concomitant medications. However, it has been found previously that induction agents have a far greater impact on seizure adequacy than does concomitant medication. 37 Further, 24% of the treated patients did not consent for their data to be added to the register. We assume that data from those treatment courses would not have changed our results, but we do not have data to confirm this.
Our data indicate that the routine use of remifentanil for reducing the anaesthetic dose with the aim of optimising seizure adequacy did not translate into a favourable clinical outcome. Given the lack of an obvious favourable clinical outcome, the practice of routinely adding remifentanil to barbiturate anaesthesia should be reconsidered. This is in line with the recommendation of Loo and colleagues 34 that the use of remifentanil should be restricted to patients with high seizure thresholds that impede the induction of adequate seizures. This explorative register-based study found that using adjunctive remifentanil and lower doses of the induction agent for ECT anaesthesia was associated with more shortterm side-effects and did not result in any favourable longterm clinical effects. The practice of routinely adding remifentanil to barbiturate anaesthesia in ECT is not justified by our register-based data, but only an adequately powered RCT could give definitive answers to this question. 
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